2013 – 2014
Main Pharmacist/Unblinded Sub-Investigator – Randomized, Multicenter, Double‐Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Versus Doripenem in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a GramNegative Pathogen in Hospitalized Adults
2015 – 2016
Unblinded Sub-Investigator – multi-center, randomized, double-blind, double – dummy study to evaluate the efficaty, safety and tolerability of carbavance (meropenem/RPX7009)comperad to piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis in adults
2016
Unblinded Sub-Investigator – Multi-center,randomized, double-blind,comparative study to evaluate the safety and efficacy of ZTI-01 versus piperacillin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults
2018 – 2019
Unblinded Sub-Investigator – Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults
2019 – 2020
Unblinded Sub-Investigator – A prospective, randomized, multi-center, double-blind, double dummy study of efficacy, tolerability and safety of intravenous sulopenem by oral sulopenemetzadroxil with probenecid versus intravenous ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate for treatment of complicated urinary tract infections in adults
2019 – 2020
Unblinded Sub-Investigator – Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficasy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide ( SPR994) Compared to
Intravenous Ertapenem in Patients with Complicated Urinary Tract Infections(cUTI) or Acute Pyelonephritis (AP)